Cite Filings / ALNY / 0002100121-26-001039
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13G

Statement of Beneficial Ownership

ALNYLAM PHARMACEUTICALS, INC. · Filed 2026-10-30 · Acc 0002100121-26-001039

Documents 1

  • SCHEDULE 13G Statement of Beneficial Ownership , xslSCHEDULE_13G_X02/primary_doc.xml

Around this filing

  • 2026-11-16 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-11-05 8-K Executive or director change · Other events
  • 2026-11-05 SCHEDULE 13G/A Statement of Beneficial Ownership
  • 2026-10-30 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-10-29 10-Q Quarterly Report
  • 2026-10-29 8-K Results of operations
  • 2026-04-29 SCHEDULE 13G Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G · T. Rowe Price Investment Management, Inc. 7.5%
  2. 2026-11-13 SCHEDULE 13G/A · Capital World Investors 10.4%
  3. 2026-11-13 SCHEDULE 13G/A · Capital Research Global Investors 8.2%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…